Sacubitril/Valsartan Plus Ivabradine Improves Outcomes in CRS Patients: Study

Combination therapy with sacubitril/valsartan and ivabradine was effective in treating cardiorenal syndrome (CRS), showing superior improvement across multiple clinical indicators and a lower incidence of major adverse cardiovascular events (MACE).

Cardiorenal syndrome (CRS) is a complex clinical condition characterized by the bidirectional interaction between cardiac and renal dysfunction, where impairment of one organ can lead to the deterioration of the other. CRS is associated with increased morbidity, mortality, repeated hospitalizations, and poor quality of life, posing a substantial burden on healthcare systems worldwide. Effective management of CRS remains challenging because of its multifactorial pathophysiology involving hemodynamic abnormalities, neurohormonal activation, oxidative stress, and metabolic disturbances. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has shown significant benefits in improving cardiac function and reducing cardiovascular events in patients with heart failure. Similarly, ivabradine, a selective inhibitor of the sinoatrial node If current, can reduce heart rate and improve cardiovascular outcomes without negatively affecting myocardial contractility. The combined use of these agents may provide synergistic therapeutic benefits in CRS by improving bot

Therefore, this study aimed to investigate the therapeutic effects of sacubitril/valsartan combined with ivabradine in patients with cardiorenal syndrome and to evaluate its impact on clinical efficacy, lipid metabolism, cardiac and renal function, oxidative stress, and major adverse cardiovascular events (MACE). Information from 120 selected participants was retrospectively analyzed and divided into an experimental group (n=60) and a control group (n=60). The control group received sacubitril/valsartan alone, while the experimental group received sacubitril/valsartan plus ivabradine. Clinical efficacy, blood lipids, cardiac and renal function, and oxidative stress were observed in both groups. The experimental group showed better clinical efficacy, lipid metabolism, cardiac function, renal function, and oxidative stress than the control group, and a lower incidence of major adverse cardiovascular events (MACE) (all P<0.05). Sacubitril/valsartan combined with ivabradine is effective in treating CRS patients, with superior efficacy across various indicators and its usage has a lower incidence of MACE.